Teclistamab is the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. Teclistamab was approved for medical use in the European Union in August 2022, and in the United States in October 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
